Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

OBJECTIVE: Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. DESIGN: Patients with RAS mutant mCRC with biopsiable metastas...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Gut
Auteurs principaux: Khan, Khurum, Rata, Mihaela, Cunningham, David, Koh, Dow-Mu, Tunariu, Nina, Hahne, Jens C, Vlachogiannis, George, Hedayat, Somaieh, Marchetti, Silvia, Lampis, Andrea, Damavandi, Mahnaz Darvish, Lote, Hazel, Rana, Isma, Williams, Anja, Eccles, Suzanne A, Fontana, Elisa, Collins, David, Eltahir, Zakaria, Rao, Sheela, Watkins, David, Starling, Naureen, Thomas, Jan, Kalaitzaki, Eleftheria, Fotiadis, Nicos, Begum, Ruwaida, Bali, Maria, Rugge, Massimo, Temple, Eleanor, Fassan, Matteo, Chau, Ian, Braconi, Chiara, Valeri, Nicola
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2018
Sujets:
Colon
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204951/
https://ncbi.nlm.nih.gov/pubmed/28790159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2017-314178
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires